查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675812

2025 年至 2033 年按产品类型、配销通路、疾病类型和地区分類的人类胰岛素市场规模、份额、趋势和预测

Human Insulin Market Size, Share, Trends and Forecast by Product Type, Distribution Channel, Disease Type, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球人类胰岛素市场规模价值为 513.3 亿美元。北美目前占据市场主导地位，到 2024 年的市场份额将超过 46.5%。

人类胰岛素是一种胜肽类激素，是人体内葡萄糖代谢的重要调节因子。它是由胰臟β细胞产生，在维持正常血糖水平中起着根本作用。人类胰岛素有多种形式，包括短效、中效和长效製剂。它广泛用于治疗第 1 型糖尿病、糖尿病酮症酸中毒 (DKA)、妊娠期糖尿病和第 2 型糖尿病。它有助于实现最佳血糖控制并最大限度地降低与疾病相关的长期併发症的风险。人类胰岛素也具有更高的安全性和有效性，因为它与人体天然的胰岛素产生过程非常相似。

政府实施的支持性政策提高了人们对糖尿病治疗的认识，并提供高品质的医疗服务，促进了市场的成长。此外，个人化医疗和精准治疗的转变趋势正在促进产品需求，因为它允许调整剂量和客製化胰岛素治疗方案，从而改善患者的治疗效果。除此之外，製造商积极的营销和促销活动提高了品牌知名度，增强了知名度并吸引了新客户，从而推动了市场成长。此外，大众对人类胰岛素重要性的认识和教育不断增强，这也推动了市场的成长。其他因素，包括医疗保健基础设施的快速扩张、对开发先进生产方法的投资增加以及主要参与者之间日益增长的合作伙伴关係，预计将推动市场成长。

人类胰岛素市场趋势/驱动因素：

糖尿病发生率不断上升

人类胰岛素在糖尿病（一种以血糖升高为特征的慢性代谢紊乱）的治疗和管理中起着至关重要的作用。它广泛应用于胰岛素替代、个人化治疗和特定疾病的管理。此外，该产品广泛应用于第 1 型糖尿病治疗，提供人体无法产生的必要胰岛素，有助于调节血糖水平和预防高血糖，从而支持了市场的成长。此外，它还可以作为口服药物来补充身体的胰岛素供应并提高葡萄糖的利用率。除此之外，胰岛素帮浦治疗中产品采用率的不断提高，可以全天持续供应胰岛素，模仿健康胰臟的基础胰岛素分泌，也促进了市场的成长。此外，人体胰岛素在术前和重症监护中发挥关键作用，以防止血糖波动并降低手术併发症的风险。

老年人口不断增加

对于患有糖尿病的老年族群，人类胰岛素在实现最佳血糖控制方面起着至关重要的作用。它可以根据年龄、病史、肾功能和整体健康状况等因素进行个人化治疗和精确剂量调整，以满足老年人的特定需求。此外，人类胰岛素具有良好的安全性，几十年来一直用于治疗糖尿病，与较新的治疗方法相比，对老年人群的风险较小。此外，与某些其他糖尿病药物相比，它有助于最大限度地降低老年族群发生低血糖的风险。除此之外，人类胰岛素可以透过多种方式给药，包括胰岛素笔、注射器和胰岛素泵，这使得医疗保健提供者能够根据老年人的需求和喜好选择最合适的胰岛素输送方法。

人类胰岛素生产的快速进步

重组脱氧核糖核酸 (DNA) 技术的引入消除了从动物中提取胰岛素的需要，提供了更稳定、可靠的胰岛素来源，对市场成长产生了积极影响。此外，利用连续生产流程可以连续不间断地生产胰岛素，从而提高效率和生产力，减少时间，节省成本，并能够快速回应需求的变化，从而促进市场的成长。此外，生物加工技术的最新进展，如发酵条件、培养基配方和细胞培养过程的最佳化，有助于降低生产成本，同时保持较高的产品质量，从而支持市场的成长。此外，色谱法、过滤和基于亲和力的分离等先进加工技术的集成，提高了胰岛素净化的效率和有效性，从而增强了市场的成长。

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球人类胰岛素市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第六章：市场区隔：依产品类型

  • 药物
    • 市场区隔：按类型
      • 人类胰岛素类似物和生物相似药
        • 快速作用
        • 长效
        • 预混
      • 人类胰岛素生物製剂
        • 短效
        • 中级表演
        • 预混
    • 市场预测
  • 输送设备
    • 市场趋势
    • 市场区隔：按类型
      • 钢笔
        • 可重复使用的笔
        • 免洗笔
      • 笔针
        • 标准笔针
        • 安全笔针
      • 注射器
      • 其他的
    • 市场预测

第七章：市场区隔：按配销通路

  • 零售药局
  • 医院药房
  • 网路零售店
  • 其他的

第 8 章：市场区隔：依疾病类型

  • I 型糖尿病
  • II 型糖尿病

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格指标

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company (BD)
    • Biocon
    • Eli Lilly and Company
    • Gulf Pharmaceutical Industries (Julphar)
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Groupe Sanofi
    • SEDICO Co.
    • Wockhardt Limited
    • Ypsomed AG
Product Code: SR112025A1950

The global human insulin market size was valued at USD 51.33 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 85.10 Billion by 2033, exhibiting a CAGR of 5.70% from 2025-2033. North America currently dominates the market, holding a market share of over 46.5% in 2024. The growing incidences of diabetes, rising geriatric population, rapid advancements in human insulin production, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

Human insulin refers to a peptide hormone that serves as a vital regulator of glucose metabolism within the human body. It is produced by pancreatic beta cells and plays a fundamental role in maintaining normal blood sugar levels. Human insulin is available in various forms, including short-acting, intermediate-acting, and long-acting formulations. It is widely used for the management of type 1 diabetes, diabetic ketoacidosis (DKA), gestational diabetes, and type 2 diabetes. It aids in achieving optimal blood glucose control and minimizing the risk of long-term complications associated with the disease. Human insulin also offers enhanced safety and efficacy profile, as it closely mimics the body's natural insulin production.

The implementation of supportive government policies to increase awareness regarding diabetes treatment and provide access to high-quality healthcare facilities is contributing to the market growth. Furthermore, the shifting trends towards personalized medicine and precision therapies are facilitating product demand as it allows dosage adjustments and customized insulin regimens, which improves patient outcomes. Besides this, aggressive marketing and promotional activities by manufacturers to improve brand visibility, increase awareness, and attract new customers are propelling the market growth. Moreover, the growing awareness and education among the masses regarding the importance of human insulin is supporting the market growth. Other factors, including the rapid expansion of the healthcare infrastructure, increasing investment in developing advanced production methods, and growing partnerships between key players, are anticipated to drive the market growth.

Human Insulin Market Trends/Drivers:

The growing incidences of diabetes

Human insulin plays a vital role in the treatment and management of diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels. It is widely used in insulin replacement, individualized therapy, and the management of specific conditions. Furthermore, the widespread product utilization in type 1 diabetes treatment to provide necessary insulin that bodies cannot produce, thus aiding in regulating blood sugar levels and preventing hyperglycemia, is supporting the market growth. Additionally, it is taken as an oral medication to supplement the body's insulin supply and improve glucose utilization. Apart from this, the rising product adoption in insulin pump therapy to deliver a continuous supply of insulin throughout the day, mimicking the basal insulin secretion of a healthy pancreas, is contributing to the market growth. Moreover, human insulin plays a critical role in preoperative and critical care settings to prevent glucose fluctuations and reduce the risks of surgical complications.

The rising geriatric population

Human insulin plays a crucial role in achieving optimal glycemic control in the geriatric population suffering from diabetes. It allows for individualized therapy and precise dosage adjustments to meet the specific needs of aging individuals based on factors such as age, medical history, renal function, and overall health status. Furthermore, human insulin has a well-established safety profile and has been used for decades in the treatment of diabetes, making it less risky for the geriatric population compared to newer treatments. Additionally, it aids in minimizing the risk of hypoglycemia in the elderly population compared to certain other diabetes medications. Apart from this, human insulin can be administered through various methods, including insulin pens, syringes, and insulin pumps, which allows healthcare providers to choose the most appropriate insulin delivery method based on the needs and preferences of geriatric individuals.

Rapid advancements in human insulin production

The introduction of recombinant deoxyribonucleic acid (DNA) technology, which eliminates the need for animal-based insulin extraction and provides a more consistent and reliable source of insulin, is positively influencing the market growth. Furthermore, the utilization of a continuous manufacturing process, which improves efficiency and productivity by allowing continuous and uninterrupted production of insulin, reducing time, saving cost, and enabling rapid response to changes in demand, is contributing to the market growth. Additionally, the recent advancements in bioprocessing techniques, such as the optimization of fermentation conditions, media formulation, and cell culture processes, which aid in reducing production costs while maintaining high product quality, are supporting the market growth. Moreover, the integration of advanced processing techniques, such as chromatography, filtration, and affinity-based separations, to improve the efficiency and effectiveness of insulin purification is strengthening the market growth.

Human Insulin Industry Segmentation:

Breakup by Product Type:

  • Drugs

Human Insulin Analogs and Biosimilars

  • Rapid Acting
  • Long Acting
  • Premixed
  • Human Insulin Biologics
  • Short Acting
  • Intermediate Acting
  • Premixed
  • Delivery Devices
  • Pens
  • Reusable Pens
  • Disposable Pens
  • Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles
  • Syringes
  • Others

Drugs dominate the market

Drugs are dominating the market growth as they have been extensively researched and proven to be effective in managing diabetes. Furthermore, their established market presence has created familiarity and confidence among prescribers, leading to their continued dominance. Apart from this, human insulin drugs are generally more accessible and affordable compared to newer, patented insulin alternatives. Their easy accessibility and affordability have contributed to the widespread use of these drugs, particularly in resource-limited settings. Besides this, they have received regulatory approvals from health authorities around the world, which ensure that human insulin drugs meet quality standards and efficacy requirements. Moreover, human insulin drugs have been widely accepted by patients with diabetes due to their long history of use and proven effectiveness.

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

Retail Pharmacies dominate the market

Retail pharmacies are situated in easily accessible locations, such as shopping centers, neighborhoods, and urban areas, which makes it convenient for patients with diabetes to access their prescribed medications. Furthermore, they have an extensive network of stores with multiple locations across cities, regions, and countries, which ensures that patients can find a nearby retail pharmacy to fill their human insulin prescriptions, irrespective of their location. Additionally, retail pharmacies have established relationships with various insurance providers and government healthcare programs, allowing for smooth reimbursement processes. Moreover, they provide additional services beyond prescription dispensing, including the proper use of human insulin, injection techniques, blood glucose monitoring, and lifestyle modifications.

Breakup by Disease Type:

  • Type I Diabetes
  • Type II Diabetes

Type I diabetes holds the largest market share

Type 1 diabetes holds the majority market share owing to its widespread prevalence across the globe. Furthermore, individuals with type 1 diabetes require insulin from the time of diagnosis throughout their lives. This substantial need for human insulin necessitates its steady supply to meet the rising demand for insulin replacement therapy. Furthermore, the absence of natural insulin production in type 1 diabetes creates a significant market demand as the primary source of insulin replacement. Along with this, human insulin provides a closer match to the insulin needs of individuals with type 1 diabetes compared to other insulin analogs, as it is structurally identical to the insulin naturally produced in the human body.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market, accounting for the largest human insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the market as it has a significant burden of diabetes, with both type 1 and type 2 diabetes being prevalent in the region. Furthermore, it boasts a well-developed healthcare infrastructure characterized by advanced medical facilities, research institutions, and pharmaceutical companies, which supports the production, distribution, and accessibility of human insulin. Additionally, North America is at the forefront of technological advancements in the healthcare sector, including the development of innovative insulin delivery systems, such as insulin pens and insulin pumps, which enhance the administration and effectiveness of human insulin. Moreover, the presence of several leading pharmaceutical companies that are actively engaged in the production and distribution of human insulin is acting as another growth-inducing factor. Apart from this, North America has well-established regulatory bodies which ensure the safety, efficacy, and quality of pharmaceutical products, including human insulin.

Competitive Landscape:

The leading companies in the market are investing in research and development (R&D) projects to create innovative human insulin products. They are focusing on improving the pharmacokinetics, delivery systems, and formulations of insulin to enhance patient convenience and adherence. Apart from this, companies are expanding their presence in emerging markets due to the growing diabetic population and increasing healthcare access. Additionally, they are establishing partnerships with local distributors, healthcare providers, and regulatory authorities to navigate the regulatory landscape and ensure the availability of their human insulin products. Moreover, several key players are developing a range of insulin formulations with varying durations of action, which allows them to capture a broader market share and meet the specific requirements of patients with different types of diabetes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • B. Braun Melsungen AG
  • Becton
  • Dickinson and Company (BD)
  • Biocon
  • Eli Lilly and Company
  • Gulf Pharmaceutical Industries (Julphar)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Groupe Sanofi
  • SEDICO Co.
  • Wockhardt Limited
  • Ypsomed AG

Key Questions Answered in This Report

  • 1.What is human insulin?
  • 2.How big is the global human insulin market?
  • 3.What is the expected growth rate of the global human insulin market during 2025-2033?
  • 4.What are the key factors driving the global human insulin market?
  • 5.What is the leading segment of the global human insulin market based on the product type?
  • 6.What is the leading segment of the global human insulin market based on the distribution channel?
  • 7.What is the leading segment of the global human insulin market based on the disease type?
  • 8.What are the key regions in the global Human Insulin market?
  • 9.Who are the key players/companies in the global Human Insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Type
      • 6.1.2.1 Human Insulin Analogs and Biosimilars
        • 6.1.2.1.1 Rapid Acting
          • 6.1.2.1.1.1 Market Trends
          • 6.1.2.1.1.2 Market Forecast
        • 6.1.2.1.2 Long Acting
          • 6.1.2.1.2.1 Market Trends
          • 6.1.2.1.2.2 Market Forecast
        • 6.1.2.1.3 Premixed
          • 6.1.2.1.3.1 Market Trends
          • 6.1.2.1.3.2 Market Forecast
      • 6.1.2.2 Human Insulin Biologics
        • 6.1.2.2.1 Short Acting
          • 6.1.2.2.1.1 Market Trends
          • 6.1.2.2.1.2 Market Forecast
        • 6.1.2.2.2 Intermediate Acting
          • 6.1.2.2.2.1 Market Trends
          • 6.1.2.2.2.2 Market Forecast
        • 6.1.2.2.3 Premixed
          • 6.1.2.2.3.1 Market Trends
          • 6.1.2.2.3.2 Market Forecast
    • 6.1.3 Market Forecast
  • 6.2 Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Breakup by Type
      • 6.2.2.1 Pens
        • 6.2.2.1.1 Reusable Pens
        • 6.2.2.1.2 Disposable Pens
      • 6.2.2.2 Pen Needles
        • 6.2.2.2.1 Standard Pen Needles
        • 6.2.2.2.2 Safety Pen Needles
      • 6.2.2.3 Syringes
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hospital Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Retail Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Type I Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type II Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 B. Braun Melsungen AG
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton, Dickinson and Company (BD)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biocon
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Gulf Pharmaceutical Industries (Julphar)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novo Nordisk A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Groupe Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SEDICO Co.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Wockhardt Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Ypsomed AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Insulin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2024
  • Figure 4: Global: Human Insulin Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Human Insulin Delivery Devices Market: Breakup by Type (in %), 2024
  • Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2024
  • Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
  • Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
  • Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
  • Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
  • Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million USD), 2019 & 2024
  • Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million USD), 2025-2033
  • Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
  • Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
  • Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: North America: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: United States: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Canada: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: China: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Japan: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: India: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: South Korea: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Australia: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Europe: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Germany: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: France: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Italy: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Spain: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Russia: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Others: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Latin America: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Brazil: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Mexico: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Others: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Global: Human Insulin Industry: SWOT Analysis
  • Figure 99: Global: Human Insulin Industry: Value Chain Analysis
  • Figure 100: Global: Human Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Insulin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Human Insulin Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 4: Global: Human Insulin Delivery Devices Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Human Insulin Market: Competitive Structure
  • Table 9: Global: Human Insulin Market: Key Players